Skip to main content

Table 4 Hurdles on the road of developing novel treatments for ALS and FTD

From: From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline

• Unknown etiology of sporadic cases.
• High degree of heterogeneity at clinical, neuropathological level.
• High degree of genetic heterogeneity both at allele and at locus level.
• Unknown reason(s) for the selective vulnerability of cell types (i.e., specific motor neurons, frontal, and temporal neurons).
• Unknown influence of exogenous factors on the onset and progression of the diseases.
• Unknown influence of endogenous modifier factors on the onset and progression of disease.